Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of CERC-301 in patients with neurogenic Orthostatic Hypotension (nOH) associated with Parkinson's disease.

Trial Profile

Phase 1 study of CERC-301 in patients with neurogenic Orthostatic Hypotension (nOH) associated with Parkinson's disease.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Rislenemdaz (Primary)
  • Indications Orthostatic hypotension; Parkinson's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Cerecor
  • Most Recent Events

    • 01 Aug 2018 According to a Cerecor media release, Dr. Stuart Isaacson from Neurology, Herbert Wertheim College of Medicine is the lead investigator for this trial.
    • 01 Aug 2018 According to a Cerecor media release, first patient has been enrolled, and data are expected in the first half of 2019.
    • 01 Aug 2018 Status changed from planning to recruiting, according to a Cerecor media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top